ライフサイエンスコーパス: recurrent cancer

1 gressive, with poorer survival compared with recurrent cancer.

2 Most patients (62%) had recurrent cancer.

3 ng for an elderly parent or for a child with recurrent cancer.

4 and clinical follow-up failed to demonstrate recurrent cancer.

5 is unique population, with a limited risk of recurrent cancer.

6 ells (TIC) is vital to combat advanced-stage recurrent cancers.

7 ere twice as likely to be from biochemically recurrent cancers.

8 ) early after transplantation, and 2 (1 with recurrent cancer, 1 with HIV infection) showed HBsAg(+).

9 Of the 21 newly diagnosed or recurrent cancers, 16 (76%) were detected by FDG PET wit

10 c and clinical criteria, suggests that these recurrent cancers actually represent new primary breast

11 thin tumors that are thought to give rise to recurrent cancer after therapy.

12 years, 256 recipients died, 35 (13.7%) from recurrent cancer and 27 (10.5%) from de novo cancer.

13 h resected colorectal cancer are at risk for recurrent cancer and metachronous neoplasms in the colon

14 t the concept that AR is fully functional in recurrent cancer and suggest a model by which a poised b

15 ing tumors in initial staging, management of recurrent cancer, and monitoring of therapy response.

16 ain and symptom management, and treatment of recurrent cancer are critical competencies of education

17 However, the search for a recurrent cancer-associated gene alteration that causes

18 e-genome analysis approaches are identifying recurrent cancer-associated somatic alterations in nonco

19 ifications in the TERT promoter; reverting a recurrent cancer-associated TERT promoter mutation in a

20 r, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adj

21 Patients with recurrent cancer bear the burden of these effects along

22 almost always followed by relapse, with the recurrent cancer being resistant to further treatments.

23 adiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from

24 Development of recurrent cancer, de novo cancer, and patient survival w

25 US-guided FNAB of 25 (64%) of the 39 recurrent cancers depicted at US was performed.

26 Twenty-one (54%) of the 39 recurrent cancers depicted at US were clinically occult.

27 Finally, we evaluated recurrent cancers from patients whose primary BRCA2-muta

28 Recurrent cancer has developed in only 1 patient.

29 gin status is more important than primary or recurrent cancer in predicting long-term outcome.

30 However, the disease recurs, and this recurrent cancer is referred to as castration-resistant

31 more than 10 ng/mL and Gleason score of the recurrent cancer more than or equal to 9 are unlikely to

32 Waiting period was not associated with recurrent cancer mortality or all-cause mortality (both

33 h nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an

34 years, 24 pregnant patients with primary or recurrent cancer of the breast were managed by outpatien

35 up (tonsillitis requiring surgery [grade 3]; recurrent cancer of the vulva [grade 4]) and six serious

36 edure in the work-up of all suspected and/or recurrent cancer patients.

37 would help detect an estimated 12 additional recurrent cancers per 1000 women screened, providing an

38 fferentiation significantly increases in the recurrent cancer relative to the primary cancer, a chara

39 Subgroup analysis of new and recurrent cancers separately, type of immune-modulator t

40 We recommend that patients with advanced and recurrent cancer should be offered early, comprehensive

41 Thus, we describe a recurrent cancer-specific lesion at the level of ubiquit

42 common nidus for the primary cancer and the recurrent cancer that arises after treatment failure.

43 structed breasts depicted 14 (56%) of the 25 recurrent cancers that were detected at US in these pati

44 Seventeen patients died of recurrent cancer, two died of second primary cancers, an

45 Recurrent cancer was determined to be present or absent

46 Significant differences between primary and recurrent cancer were found for transport k(1), influx K

47 cteristic curve for the detection of locally recurrent cancer with MR imaging was 0.49 and 0.51 for r